Mutant TP53 has been shown to co-operate with oncogenic KRAS in the formation of PDAC tumors in mouse models (Bailey et al., 2016) and in pancreatic cancer metastasis (Weissmueller et al., 2014). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.